The Translational Genomics Research Institute

Novartis Ag

Mayo Foundation for Medical Education and Research

Keith Stewart

Michael Richard Barrett

George Vasmatzis

David Craig

Mitesh J Borad

John Carpten

Sara Byron

Jessica Aldrich

Alan Bryce

Carla C Heise

Michael Rowe

Edward Moler

Esther Masih-Khan

Suzanne Trudel

Various embodiments provide compositions and methods for detecting cancers containing an NRG1 fusion event and treating a patient with a therapeutic agent that is targeted to the NRG1 fusion. Exemplary compositions for treating cancers containing the NRG1 fusion may comprise therapeutic agents inhibiting Epidermal Growth Factor Receptor and/or ERBB2 such as cetuximab, panitumumab, Sym004, MM-151, mAb 806, mAb 528, MEHD794A, gefitinib, erlotinib, lapatinib, afatinib, PD153035, AG1478, trastuzumab, and pertuzumab. In some embodiments, the therapeutic agent may be a combination of trastuzumab, and pertuzumab.

Targeted therapies for cancer

Methods of utilizing biomarkers to identify patients for treatment or to monitor response to treatment are taught herein. Alterations in levels of gene expression of the biomarkers, particularly in response to FGFR3 inhibition, are measured and identifications or adjustments may be made accordingly.

Effects of inhibitors of FGFR3 on gene transcription

Growing community of inventors

Scottsdale, AZ, United States of America

Keith Stewart